Clinical Trial Update: To Evaluate the Safety and Efficacy of Human Derived Anti-BCMA CAR-T Injection for Subjects with R/R MM [EARLY_Phase 1]

View source ↗

Summary

Early-phase clinical trial evaluating the safety and efficacy of a human-derived anti-BCMA CAR-T cell therapy for relapsed/refractory multiple myeloma; the stud…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Human-Derived Anti-BCMA CAR-T Injection (anti-BCMA CAR-T cell therapy)

Snippet

Sponsor: Hrain Biotechnology Co., Ltd. | Conditions: Multiple Myeloma | EARLY_Phase 1 | Status: ACTIVE_NOT_RECRUITING